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and Acronyms
CRP = C-reactive protein
CT = computed tomography
FDG = 18F-ﬂuorodeoxyglucose
HDL = high-density
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LDL-C = low-density
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PD = periodontal disease
PET = positron emission
tomography
ROI = region of interest
SUV = standardized uptake
value
TBR = target-to-background
ratio
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2383in the United States alone (2). Moreover, PD is a com-
mon, independent risk factor for atherosclerotic disease
(3,4). Multiple pathogenic mechanisms linking PD and
cardiovascular disease have been proposed. Most prominently,
local periodontal inﬂammation, through pro-inﬂammatory
cytokine release, leads to increased systemic inﬂammation as
measured by C-reactive protein (CRP), tumor necrosis factor-a,
interleukin-6, and other biomarkers (5–7). Augmented cir-
culating inﬂammatorymediators, in turn, promote inﬂammatory
activity within atherosclerotic plaque (8,9). Interestingly, local
treatment of PD has also been shown to reduce systemic
inﬂammation in patients with a history of cardiovascular events
(10). To date, however, no deﬁnitive evidence exists that treat-
ment of PD decreases cardiovascular disease progression or
cardiovascular events.
18F-ﬂuorodeoxyglucose (FDG) positron emission to-
mography (PET) imaging provides a noninvasive measure of
inﬂammation, including inﬂammatory activity within
atherosclerotic plaques. Several studies have demonstrated
a strong correlation between carotid FDG uptake with
histopathological measures of macrophage inﬁltration and
inﬂammatory gene expression (11–15). The arterial FDG
signal is reproducible (16), correlates with atherosclerotic
inﬂammatory burden, and is modiﬁable by antiathero-
sclerotic therapies (17–20). We have previously demon-
strated that periodontal inﬂammation correlates with carotid
artery inﬂammation (21), and, most recently, others have
shown that periodontal FDG uptake correlates with PD
severity as measured by alveolar bone loss (22).
5-hydroxy-3-methylglutaryl-coenzyme A reductase in-
hibitors, so called “statins,” have clear beneﬁts in athero-
sclerotic diseases (23). These drugs effectively decrease
low-density lipoprotein cholesterol (LDL-C) levels and
have other beneﬁcial pleiotropic effects beyond lipid lowering,
especially with respect to reducing systemic inﬂammation and
also inﬂammatory activity within atherosclerotic plaques
(17,24). Multiple retrospective epidemiologic studies have
demonstrated that statin therapy is also associated with
reduced severity of periodontitis (25–28). Most recently,
a small prospective study suggested an additional beneﬁt of
combined statin and standard local periodontal treatment
compared with standard local therapy alone (29). Neverthe-
less, the direct anti-inﬂammatory actions of statins in peri-
odontal tissue have not been previously demonstrated.
Accordingly, we used FDG-PET/computed tomography
(CT) imaging to evaluate a potentially novel pleiotropic effect
of statin treatment on periodontal tissue. We speciﬁcally
tested the hypothesis that atorvastatin treatment would lower
PD activity, mirroring its action on atherosclerotic plaque
activity (20), and thereby providing a link between both
disease states.
Methods
Study design. This double-blind, randomized, active-
comparator study (NCT00703261) was conducted at 10U.S. centers in order to study
the impact of high-dose statin
therapy on arterial inﬂammation.
The protocol was reviewed and
approved by each center’s insti-
tutional review board, and all
participants provided written in-
formed consent prior to any study
procedures. In the current study,
we performed a separate, blinded
analysis of FDG uptake in the
periodontium to assess the impact
of statin treatment on periodontal
tissue inﬂammation. Permission
was received from the Partners
Healthcare Institutional Review
Board to evaluate PD indexes on
the anonymized imaging data.Patients. A total of 163 subjects were initially screened,
and 83 subjects (median age 59 years, range: 37 to 78 years,
78% men) were randomized in this study. Men and
women 30 to 80 years of age were included if they had
documentation or history of any 1 of the following: 1)
carotid artery disease; 2) coronary artery disease; 3) cere-
brovascular disease; 4) peripheral arterial disease (ankle-
brachial index 0.5 and 0.9); 5) type 2 diabetes mellitus;
or 6) body mass index 30 to 40 kg/m2 (inclusive) and waist
circumference >102 cm in men and >88 cm in women.
Patients were excluded if they had a history of: 1) type 1
diabetes mellitus; 2) any signiﬁcant cardiovascular event or
intervention within 12 weeks of screening; 3) signiﬁcant
heart failure (e.g., New York Heart Association functional
class III or IV, deﬁbrillators); 4) active or chronic hep-
atobiliary disease; or 5) a chronic systemic inﬂammatory
condition (such as rheumatoid arthritis or psoriasis) or
chronic infection. Additionally, eligible subjects were
required to have LDL-C 60 mg/dl, to have a triglyceride
level <350 mg/dl, and to be statin naïve or taking no more
than low-dose statins (deﬁned as: atorvastatin 10 mg,
simvastatin 20 mg, rosuvastatin 5 mg, pravastatin
40 mg, or ﬂuvastatin 40 mg).
After the initial clinical screening, patients underwent
baseline imaging using FDG-PET/CT. Because the parent
study was designed to evaluate the effect of statin treat-
ment on arterial inﬂammation, subjects without evidence
of any arterial inﬂammation at baseline were excluded
from randomization (i.e., target-to-background ratio
[TBR] 1.6 present in either aorta, right or left carotid),
which resulted in the exclusion of approximately 10% of
the initially screened population. Eligible patients were
randomized (after prior statin therapy was discontinued) in
a double-blinded manner to a 10-mg atorvastatin tablet
(Lipitor, Pﬁzer, New York, New York) plus an 80-mg
atorvastatin matching placebo daily or an 80-mg atorvas-
tatin tablet plus a 10-mg atorvastatin matching placebo
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2384daily for 12 weeks. Following randomization, FDG-PET/
CT images were obtained again after 4 and 12 weeks.
Seventy-one subjects completed the 12-week drug treat-
ment period. In 12 subjects, coverage of the mouth was not
included within the PET/CT ﬁeld of view; hence, the ﬁnal
analysis set for the current study included 59 subjects
(Fig. 1).
FDG-PET/CT imaging. FDG-PET/CT imaging was
performed using previously validated methods (11,12).
Patients were asked to adhere to a low-carbohydrate diet for
24 h before the test and to fast overnight prior to imaging.
Imaging was performed 2 h after administration of 10 mCi
of 18F-FDG, and images were acquired in 3-dimensional
mode over 15 min. The image data were attenuation-
corrected and reconstructed using ordered-subsets expecta-
tion-maximization algorithm. Blood sugar concentration
was <200 mg/dl at the time of imaging for all subjects.
Measurement of periodontal tissue FDG uptake with
PET. PET and CT images were analyzed using previously
detailed methods (21). Investigators were blinded to the
clinical history, randomization details, and temporal se-
quence of imaging time points. Subsequently, the datasets
(week 0, 4, and 12 images) were batch analyzed after manual
coregistration of PET and CT images (Leonardo TrueD,
Siemens, Forchheim, Germany) as previously reported (21).
Coregistration was performed using anatomical landmarks
such as teeth and periodontal tissue, brain, spinal cord,
spine, and jaw. After coregistration, the periodontal tissuesFigure 1 Trial Consort Diagram
*Some subjects were excluded for more than 1 reason. Therefore, the sum of individual tot
PET ¼ positron emission tomography; PI ¼ principal investigator; TBR ¼ target-to-backgrowere identiﬁed and the maximum standardized uptake value
(SUV) of FDG was measured by drawing a rectangular
region of interest (ROI) around the teeth. The ROIs were
drawn from the mesial surface of the ﬁrst premolar to
the distal surface of the second molar teeth in each of 4
quadrants (Fig. 2). Care was taken to avoid spill-over activity
from the tongue, as well as from pharyngeal and buccal
structures. Periodontal FDG uptake around anterior teeth
(incisor and canine) and third molars (if present) were not
assessed. The TBRs were derived from the ratio of the SUV
of the periodontal tissue to background blood activity from
the internal jugular vein. The interobserver and intraobserver
correlations of periodontal TBR measurement (based on
blinded analysis of 24 subjects) were 0.986 and 0.996,
respectively. The inter-reader and intrareader variability was
4.58% and 2.36%, respectively.
Measurement of FDG uptake in carotid tissue. Carotid
FDG uptake was measured using previously described
methods (12). The ROIs were placed at each axial plane
along the length of the carotid to measure the maximum
SUV. The TBR was calculated as the ratio between the
carotid arterial and the venous blood SUV measured in the
internal jugular vein. Thereafter, FDG uptake (TBR) was
calculated using an average of the maximum TBR activity
for all of the axial segments that compose the vessel.
Assessment of periodontal bone loss. Contrast-enhanced
CT imaging was performed once (at baseline or week 4) to
provide additional anatomical information to ensure that theals is >80. CT ¼ computed tomography; FDG ¼ ﬂuorodeoxyglucose; lab ¼ laboratory;
und ratio.
Figure 2 Measurement of Periodontal FDG Uptake on an Axial Mandibular Section
Rectangular regions of interest (ROIs), shown as dotted yellow rectangles, drawn around the teeth from the premolar to the second molar in each quadrant. The maximum
standardized uptake value is then recorded for each ROI. The arrow indicates an area of a broken tooth. (A) PET, (B) CT, and (C) composite PET/CT image. Brighter red to
yellow colors represent higher FDG-PET activity. *Tongue FDG activity. Abbreviations as in Figure 1.
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2385same locations within the arterial segments are measured
across time. In 59 patients, the CT images included the oral
cavity in the ﬁeld of view, thus allowing for post-hoc eval-
uation of alveolar bones. Imaging parameters included
rotation time of 420 ms or less, a tube current of w750
mAs, and voltage of 120 kVp. Image acquisition charac-
teristics were section thicknesses of 0.75 mm and pitch of
0.2 to 0.4. Iopamidol 300 mg/ml or similar was used as an
intravenous contrast agent and was infused at 5 to 6 mls/s.
While the multisection CT image acquisition was optimized
for arterial imaging, the current and voltage used for arterial
imaging is substantially higher than that typically used
for dental imaging (30). Evaluation of the periodontal
CT images was performed by an experienced periodontist
(T.V.) blinded to all PET data, clinical information, and
treatment assignment. Alveolar bone resorption was semi-
quantitatively assessed in each of the 4 dental quadrants: 0,
1, 2, or 3 for none, mild (limited to coronal one-third of the
root), moderate (including the middle one-third of the root),
or severe (to the apical one-third of the root) bone loss,
respectively. Periodontium of anterior teeth (incisors and
canines) and third molars were not evaluated for bone
resorption scoring.
Assessment of blood biomarkers. High-sensitivity CRP,
LDL-C, and high-density lipoprotein (HDL) concentra-
tions were assessed in plasma at 0, 4, and 12 weeks. All
serum biomarker analyses were performed in batches.
Statistical analysis. The “Generalized Estimating Equa-
tions” test was used to compare FDG uptake in dental
quadrants with versus without severe PD (based on CT
evidence of alveolar bone loss). The same test was em-
ployed to adjust for the covariates in that analysis. The
Student t test was used to assess the impact of atorvastatin
treatment (80 mg compared with 10 mg) on periodontal
inﬂammation. Univariate associations were tested using
Pearson’s correlation coefﬁcient. Linear regression wasused to evaluate the independence of periodontal TBR as
a predictor of periodontal bone loss, with PD risk factors as
covariants. A forward-enter approach was employed to
evaluate the robustness of these relationships, wherein
the signiﬁcant or near-signiﬁcant (p < 0.10) variables
identiﬁed in univariate analysis were entered. Between-
group differences were based on observed data values,
without adjusting for missing data. Unstandardized re-
gression coefﬁcients are reported as b and 95% conﬁdence
interval (CI). Statistical analysis was performed using
SPSS version 20 (IBM, Armonk, New York). All reported
p values are 2-tailed; statistical signiﬁcance was set at p <
0.05. Multiplicity adjustments were not applied for
secondary comparisons of interest; as such, nominal p values
are reported for all comparisons.Results
Subject characteristics. A total of 163 patients were
screened, and 83 patients were randomized. Twelve patients
discontinued early due to: adverse experiences (n ¼ 6),
withdrawal of consent (n ¼ 2), or protocol deviation or other
reason (n ¼ 4). Of the 83 patients randomized to the study,
71 subjects completed the study; among those, periodontal
tissue images were available for 59 subjects. The demo-
graphic and clinical characteristics of the patients at the
baseline are shown in Table 1.
Relationship between PD and periodontal FDG uptake
at baseline. Periodontal FDG uptake at baseline was
compared with CT measures of alveolar bone resorption.
Mean baseline TBR was signiﬁcantly higher in quadrants
with versus without severe alveolar bone loss (dental quad-
rant TBR: 3.83 [95% CI: 3.36 to 4.30] vs. 3.18 [95% CI:
2.91 to 3.44], p ¼ 0.004) (Fig. 3). The association between
periodontal TBR and alveolar bone loss remained signiﬁcant
after adjusting for age and sex (b ¼ 0.64, p ¼ 0.005) and
Table 1 Baseline Patient Characteristics
Variables
Total
(N ¼ 59)
Atorvastatin 10 mg
(n ¼ 29)
Atorvastatin 80 mg
(n ¼ 30) p Value
Age, yrs 59.78  9.73 60.31  10.52 59.27  9.04 0.684
Male 44 (74.57) 21 (72.41) 23 (76.66) 0.882
Caucasian race 45 (76.27) 21 (72.41) 24 (80.00) 0.648
Body mass index, kg/m2 31.68  8.24 31.62  10.56 31.73  5.32 0.975
Diabetes mellitus 18 (30.50) 11 (37.93) 7 (23.33) 0.223
Current smoker 17 (28.81) 9 (31.03) 8 (26.66) 0.711
Ever smoked 30 (50.84) 16 (55.17) 14 (46.66) 0.514
Coronary artery disease 26 (44.06) 13 (44.82) 13 (43.33) 0.908
Pre-study statin use 33 (55.93) 18 (62.06) 15 (50.00) 0.351
LDL-C 104.66  26.51 103.36  24.05 105.87  28.98 0.722
hs-CRP 2.61  2.56 2.40  2.41 2.80  2.72 0.551
HDL-C 46.98  15.23 50.64  14.92 43.57  14.96 0.077
Gingival TBR 3.78  1.22 3.60  1.01 3.95  1.38 0.284
Values are mean  SD or n (%).
HDL-C ¼ high-density lipoprotein cholesterol; hs-CRP ¼ high-sensitivity C-reactive protein; LDL-C ¼ low-density lipoprotein cholesterol;
TBR ¼ target-to-background ratio.
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2386major risk factors of PD: diabetes mellitus and smoking
(b ¼ 0.65, p ¼ 0.004) (31,32).
Statins and periodontal tissue inﬂammation. We
observed a normal distribution of periodontal FDG uptake
values across the subjects in both treatment groups at
baseline and at weeks 4 and 12. In the entire cohort (before
subset selection based on the presence of periodontitis at
baseline), a signiﬁcant reduction in periodontal FDG uptake
was seen after 12 weeks of treatment with high-dose versus
low-dose atorvastatin (mean change TBR: 0.29  0.85 vs.
0.13  0.68, atorvastatin 80 mg vs. 10 mg, p ¼ 0.04)Figure 3 Lateral View of the Mandible From an Angulated Sagittal P
Degree of bone loss and FDG PET signal. (A) Patients without bone loss; (B) patients with
bone loss. Bone loss on CT is dichotomized into severe and nonsevere categories and plo
Figure 1.(Table 2). The impact of high-dose atorvastatin on PD
activity remained signiﬁcant after adjusting for: 1) age and
sex (b ¼ 0.45, p ¼ 0.034); 2) diabetes mellitus and
smoking (b ¼ 0.43, p ¼ 0.04); and 3) prior coronary artery
disease, baseline HDL, low-density lipoprotein (LDL), and
CRP levels (b ¼ 0.45, p ¼ 0.034).
Moreover, the effect of high-dose statin was more
notable in subjects with imaging evidence of PD at base-
line. In the ﬁrst PD-based subset analysis, individuals with
PD were identiﬁed based on the presence of PET evidence
of active periodontitis (subjects with the highest 2 tertileslane
severe bone loss. Dotted line indicates the estimated alveolar bone margin without
tted against the TBR (C). *p < 0.05; error bars represent SEM. Abbreviations as in
Ta
bl
e
2
S
um
m
ar
y
of
C
ha
ng
es
of
TB
R
at
4
an
d
1
2
W
ee
k
s
TB
R
E
nd
po
in
ts
(W
ee
k
s)
A
to
rv
as
ta
ti
n
1
0
m
g
A
to
rv
as
ta
ti
n
8
0
m
g
8
0
m
g
vs
.
1
0
m
g
A
to
rv
as
ta
ti
n*
0
4
1
2
D
4
D
1
2
0
4
1
2
D
4
D
1
2
D
4
D
1
2
A
ll
pa
tie
nt
sy
3
.6
0
(3
.2
2
to
3
.9
9
)
3
.7
1
(3
.3
1
to
4
.0
6
)
3
.7
9
(3
.3
0
to
4
.2
7
)
0
.0
1
4
(
0
.2
0
to
0
.2
3
)
p
¼
0
.8
9
0
.1
3
(
0
.1
3
to
0
.3
9
)
p
¼
0
.3
1
3
.9
5
(3
.4
3
to
4
.4
6
)
3
.5
8
(3
.1
7
to
3
.9
8
)
3
.6
5
(3
.1
9
to
4
.1
1
)
0
.3
9
5
(
0
.7
6
to
0
.0
3
)
p
¼
0
.0
3
5
0
.2
9
(
0
.6
1
to
0
.0
2
)
p
¼
0
.0
6
7
0
.3
8
1
(
0
.7
6
3
to
0
.0
0
)
p
¼
0
.0
5
0
.4
3
(
0
.8
3
to
0
.0
2
0
)
p
¼
0
.0
4
Su
bg
ro
up
of
pa
tie
nt
s
w
ith
m
od
er
at
e
to
se
ve
re
pe
rio
do
nt
al
di
se
as
e
at
ba
se
lin
e
P
D
(b
y
P
ET
)z
4
.0
7
(3
.7
0
to
4
.4
3
)
4
.1
0
(3
.6
7
to
4
.5
2
)
4
.2
9
(3
.8
0
to
4
.7
8
)
0
.0
2
8
(
0
.2
6
to
0
.3
2
)
p
¼
0
.8
4
4
0
.2
2
(
0
.1
4
to
0
.5
9
)
p
¼
0
.2
2
6
4
.6
4
(4
.1
4
to
5
.1
4
)
3
.9
7
(3
.5
5
to
4
.3
9
)
4
.1
2
(3
.6
1
to
4
.6
2
)
 0
.7
4
(
1
.1
9
to
0
.2
8
)
p
¼
0
.0
0
3
0
.5
2
(
0
.9
6
to
0
.0
8
)
p
¼
0
.0
2
2
0
.5
2
2
(
1
.0
3
to
0
.1
2
)
p
¼
0
.0
4
5
0
.7
4
3
(
1
.2
9
to
0
.1
8
7
)
p
¼
0
.0
1
P
D
(b
y
C
T)
x
3
.7
2
(3
.1
0
to
4
.3
4
)
3
.8
8
(3
.0
5
to
4
.7
2
)
4
.1
4
(3
.2
1
to
5
.0
6
)
0
.1
6
(
0
.2
8
to
0
.6
1
)
p
¼
0
.4
4
3
0
.4
1
(
0
.0
4
to
0
.8
8
)
p
¼
0
.0
7
4
3
.5
4
(2
.6
5
to
4
.4
4
)
3
.5
1
(2
.6
9
to
4
.3
3
)
3
.3
5
(2
.6
0
to
4
.1
0
)
0
.0
3
(
0
.4
9
to
0
.4
3
)
p
¼
0
.8
8
3
0
.1
9
(
0
.5
6
to
0
.1
7
)
p
¼
0
.2
7
8
0
.2
2
9
(
0
.8
5
to
0
.4
0
)
p
¼
0
.4
5
8
0
.6
0
9
(
1
.1
6
to
0
.0
5
4
)
p
¼
0
.0
3
3
Va
lu
es
ar
e
m
ea
n
(9
5
%
co
nﬁ
de
nc
e
in
te
rv
al
).
*G
ro
up
co
m
pa
ris
on
s
ar
e
ad
ju
st
ed
fo
r
ba
se
lin
e
gi
ng
iv
al
TB
R
.N
o
ad
ju
st
m
en
t
is
m
ad
e
fo
r
m
ul
tip
le
co
m
pa
ris
on
s.
yn
¼
3
0
fo
r
th
e
8
0
-m
g
at
or
va
st
at
in
gr
ou
p
an
d
n
¼
2
9
fo
r
th
e
1
0
-m
g
at
or
va
st
at
in
gr
ou
p.
zP
at
ie
nt
s
w
ith
lo
w
er
te
rt
ile
ba
se
lin
e
TB
R
ex
cl
ud
ed
.n
¼
2
0
fo
r
th
e
8
0
-m
g
at
or
va
st
at
in
gr
ou
p
an
d
n
¼
2
0
fo
r
th
e
1
0
-m
g
at
or
va
st
at
in
gr
ou
p.
xP
at
ie
nt
s
w
ith
C
T
ev
id
en
ce
of
m
od
er
at
e
to
se
ve
re
pe
rio
do
nt
al
bo
ne
re
so
rp
tio
n.
n
¼
1
3
fo
r
th
e
8
0
-m
g
at
or
va
st
at
in
gr
ou
p
an
d
n
¼
1
2
fo
r
th
e
1
0
-m
g
at
or
va
st
at
in
gr
ou
p.
C
T
¼
co
m
pu
te
d
to
m
og
ra
ph
y;
P
D
¼
pe
rio
do
nt
al
di
se
as
e;
P
ET
¼
po
si
tr
on
em
is
si
on
to
m
og
ra
ph
y;
TB
R
¼
ta
rg
et
-to
-b
ac
kg
ro
un
d
ra
tio
.
JACC Vol. 62, No. 25, 2013 Subramanian et al.
December 24, 2013:2382–91 Periodontal Inflammation Reduction Through Statins
2387of baseline periodontal TBR). Between-group differences
became more substantial within individuals with active
periodontitis (by PET) at baseline (change TBR: 0.52 
0.94 vs. 0.22  0.79, atorvastatin 80 mg vs. 10 mg,
p ¼ 0.01) (Fig. 4, Table 2). Furthermore, the difference in
changes in PD activity between treatment groups was
signiﬁcant starting at 4 weeks (Fig. 4, Table 2). Similarly,
in the second subgroup analysis, individuals with PD were
identiﬁed based on CT evidence of alveolar bone loss to
indicate a history of PD. In that analysis, subjects without
moderate or severe alveolar bone loss in at least 1 tooth
were excluded. In this second PD-based analysis, between-
group differences remained signiﬁcant in the subgroup of
patients with moderate to severe periodontal bone loss at
baseline as determined by CT (change in TBR: 0.19 
0.61 vs. 0.41  0.73, atorvastatin 80 mg vs. 10 mg,
p ¼ 0.033) (Table 2).
Relationship between atherosclerotic inﬂammation and
periodontal inﬂammation. Baseline FDG uptake (TBR)
in periodontal tissue correlated with baseline carotid plaque
TBR (Fig. 5). Additionally, after 12 weeks of statin therapy,
changes in periodontal inﬂammation correlated with
changes in carotid inﬂammation (Fig. 6). Moreover, subjects
with a greater than median reduction of periodontal TBR
demonstrated a signiﬁcantly greater decrease of arterial
inﬂammation after adjusting for changes of LDL-C and
CRP (b ¼ 0.29, p ¼ 0.001).
PD inﬂammation versus lipids and CRP. Baseline PD
activity (periodontal TBR) correlated inversely with baseline
HDL concentration (R ¼ 0.35, p ¼ 0.007) but did not
correlate with baseline CRP or baseline LDL. The presence
of severe alveolar bone loss (by CT) was associated withFigure 4
Change in Periodontal FDG Uptake (TBR) at
4 and 12 Weeks From the Baseline in Patients
With Active Periodontitis (by PET)
Error bars represent 95% conﬁdence interval. *p¼ 0.045; yp¼ 0.003; zp¼ 0.022;
xp ¼ 0.01. Atorva ¼ atorvastatin; other abbreviations as in Figure 1.
Figure 5
Prior to Randomization, Periodontal FDG Uptake
Correlated With Carotid Inﬂammation
FDG uptake within periodontal tissues was compared with carotid FDG uptake
(a measure of carotid inﬂammation) at baseline. A signiﬁcant relationship was
observed (r ¼ 0.67, p < 0.001). Abbreviations as in Figure 1.
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2388higher CRP concentrations (b ¼ 1.97, p ¼ 0.022), after
correcting for age, sex, smoking, and diabetes. Changes in
PD activity did not correlate with changes in CRP, LDL
or HDL.Discussion
This report demonstrates that 12 weeks of high-dose atorvas-
tatin therapy signiﬁcantly reduces periodontal inﬂammation.Figure 6
In the Setting of Statin Therapy, Changes in
Periodontal Activity Correlate With Changes in
Carotid Inﬂammation
After 12 weeks of statin treatment, a signiﬁcant relationship was observed
between changes in periodontal activity (FDG uptake measured as DTBR) and
changes in carotid arterial inﬂammation (measured as DTBR). ATV ¼ atorvastatin;
other abbreviations as in Figure 1.Between-group differences were more pronounced in
individuals with PET imaging evidence of PD. The reduc-
tion in the PD signal was observed as early as 4 weeks after
randomization and correlated with changes in FDG uptake
within the wall of the carotid artery (a marker of arterial
inﬂammation).
Periodontal FDG uptake as a marker of periodontitis.
While evaluation of malignant and infectious oral lesions
using FDG-PET is established in clinical practice, the
assessment of PD using FDG-PET imaging is relatively
novel. We have previously reported the correlation between
periodontal FDG uptake and arterial plaque inﬂammation
(21) and hypothesized that periodontal FDG uptake reﬂects
dynamic periodontal inﬂammation and, thus, the severity of
PD. Recently, Kito et al. (22) provided supportive evidence
for this contention, demonstrating that periodontal FDG
uptake is indeed correlated with PD severity as measured by
the magnitude of bone resorption on radiographs,
a destructive end result of inﬂammation (33). In the current
study, we provide further conﬁrmation of these ﬁndings and,
importantly, provide additional evidence that periodontal
FDG uptake reﬂects periodontal inﬂammation. However, in
contrast to bone loss that identiﬁes the longer-term conse-
quences of severe PD, the FDG-PET signal likely reﬂects
the current inﬂammatory burden within the target tissue and
indicates ongoing, active PD.
Relationship between periodontitis and atherosclerosis.
While an epidemiological association between PD and
atherosclerosis is well known, the degree of inﬂuence of PD
on atherosclerosis is not fully understood. Nevertheless, the
consensus of 2 independent reviews was that PD is an
independent risk factor for atherosclerosis (34,35). Imaging
studies have also established a direct association between PD
and carotid atherosclerosis by correlating increased intima-
media thickness with the extent of PD (36). Importantly,
the ICARAS (Inﬂammation and Carotid Artery–Risk from
Atherosclerosis Study) (37) revealed that PD was associated
with subsequent progression of atherosclerosis. In this study,
we provide additional evidence of a link between PD and
atherosclerosis by showing a signiﬁcant correlation between
PD and carotid imaging parameters at baseline (thus con-
ﬁrming prior studies) and additionally by demonstrating
a strong association between changes of the 2 imaging
parameters over a 12-week period upon atorvastatin treat-
ment. The close association that we observed between the 2
tissues supports the hypothesis that periodontal and
atherosclerotic inﬂammations (as assessed by FDG-PET
arterial wall imaging) are inter-related, although the nature
of that association is undeﬁned.
A novel pleiotropic effect of statins. Although it was at
ﬁrst assumed that the beneﬁcial impacts of statins were
mediated via reduction of LDL-C, multiple studies have
consistently suggested that not all actions can be accounted
for by cholesterol reduction per se. For example, in the
CARE (Cholesterol And Recurrent Events) trial (38), the
magnitude of high-sensitivity CRP reduction associated
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pronounced than the amount that would be predicted by
changes in LDL-C alone. In the PROVE IT–TIMI 22
(Pravastatin or Atorvastatin Evaluation and Infection
Therapy–Thrombolysis In Myocardial Infarction 22) trial
(39), the rapid event reduction after statin therapy was
postulated to be in part due to non–lipid-related properties
of statins. These cholesterol-independent or “pleiotropic”
effects of statins have been attributed to several mechanisms,
including improved endothelial function, decreased smooth
muscle cell proliferation, reduced platelet function, and
attenuated inﬂammation (40). Based on the ﬁndings of this
study, we pose the possibility that statins may exert an
additional pleiotropic effect: reduction of nonarterial
inﬂammation, (i.e., within inﬂamed tissues such as the
periodontium). We further postulate that a reduction in local
periodontal inﬂammation (as an example of several clinical
models of extra-arterial inﬂammation) may exert secondary
beneﬁts on the systemic arterial milieu, whereby reduction in
inﬂammation within the periodontium leads to a reduction
in proinﬂammatory mediators released by periodontal tissue
into the systemic circulation; this, in turn, may lead to
further reductions in atherosclerotic inﬂammation (Fig. 7).
Indeed, prior studies support the hypothesis that treat-
ment of PD might yield beneﬁts in atherosclerosis. For
instance, PD treatment results in reduced carotid intima-
media thickness (41), and improving oral health decreases
both local and systemic markers of inﬂammation (42,43) and
improves endothelial function (44,45). Additionally, other
extravascular inﬂammatory diseases have similarly been
linked to atherosclerotic disease. The most prominent ex-
ample is rheumatoid arthritis (RA) (46,47). Atorvastatin
therapy has proven beneﬁcial in RA in terms of modulationFigure 7
Inter-Relationships Between Arterial and
Extra-Arterial Inﬂammatory Processes
Inﬂammatory processes in multiple distinct tissues may be inter-related. Within
this paradigm, statins can have direct as well as indirect beneﬁts on arterial
inﬂammation. Statins can impact arterial inﬂammation through direct actions on
the atheromatous milieu. Additionally, statins reduce inﬂammation in extra-arterial
locations (such as periodontal tissues). Theoretically, this reduction in extra-
arterial inﬂammation may decrease chronic cytokine production by those sites,
hence decreasing pro-inﬂammatory stimulation of atherosclerotic plaques.of clinical and inﬂammatory markers (48). Further, treat-
ment of RA and psoriasis with disease-modifying anti-
inﬂammatory drugs (49) leads to a reduction in cardiovascular
risk, thereby supporting the hypothesis that extravascular
inﬂammation is an important and modiﬁable contributing
factor for the promotion of atherosclerosis. However, the
exact nature of the inter-relationship among statins, arterial
inﬂammation, and periodontal inﬂammation remains elusive
after the results of this study, and we cannot exclude the
possibility that statins may affect both periodontal and
arterial inﬂammation independently without a link bet-
ween these 2 tissues.
Future randomized, controlled studies will be needed to
examine the underlying mechanism of the association
between localized inﬂammation of extra-arterial tissues and
atherosclerosis; they will speciﬁcally be needed to test the
hypothesis that localized (nonsystemic) treatment of extra-
arterial inﬂammation reduces atherosclerotic inﬂammation
and cardiovascular risk. These studies should also evaluate
whether moderate doses of statins also confer anti-
inﬂammatory beneﬁts on the periodontium. Indeed, PD
represents an ideal model to test this hypothesis, because
treatment of periodontitis can be achieved via local inter-
vention (plaque removal and scaling) without the need for
systemic treatment.
If conﬁrmed by larger prospective outcome studies, statins
would prove to be a useful adjunctive treatment for PD, with
efﬁcacy seen within 1 month. Furthermore, the possible
inter-relationship among periodontitis, atherosclerosis, and
statins might prove to be of substantial importance due to
the high prevalence of both periodontal and atherosclerotic
diseases along with the widespread use of statins. Moreover,
additional investigations to assess the inter-relationships
between extra-arterial inﬂammation and atherosclerosis are
warranted, considering the fact that knowledge derived from
treatment of extra-arterial inﬂammatory disorders may lead
to useful insights into the inﬂammatory mechanisms of
atherosclerosis in general (47).
Study limitations. While our data suggest that high-dose
atorvastatin is more effective than low-dose treatment in
decreasing inﬂammation in atherosclerosis and PD, these
ﬁndings do not allow determination of the efﬁcacy of low-
dose treatment relative to placebo. It is worth noting in
this context that the majority of subjects that were
randomized to atorvastatin 10 mg/day were previously on
a low-dose statin prior to study entry, and, hence, they might
not have experienced a boost in the effective statin dose over
the course of the study. This might contribute to the
observation that low-dose statin treatment was not associ-
ated with a reduction in periodontal FDG uptake. None-
theless, the main observation of an effect of high-dose statin
remains valid. Further, given that 50% of subjects random-
ized to atorvastatin 80 mg were previously on a low-dose
statin, the impact of high-dose statin intervention in a sta-
tin naïve population might be more profound than seen in
the current study. Last, the ﬁndings of the current study
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subjects with PET/CT imaging evidence of atherosclerotic
disease. Hence, extrapolation of the ﬁndings of this study to
the broader population should be done cautiously. Future
randomized clinical trials are warranted in order to evaluate
the effects of statins on PD regardless of status of
atherosclerosis.
Conclusions
We observed that high-dose atorvastatin is associated with
a reduction in periodontal inﬂammation in this multicenter,
double-blind trial. The impact of high-dose statins was
greatest in individuals with evidence of active periodontitis
and was evident after a 4-week treatment period. Further-
more, we observed a close association between reductions in
periodontal and atherosclerotic inﬂammation. Accordingly,
these results identify a potentially novel pleiotropic effect of
statins and raise the possibility that an indirect beneﬁt of
statins on atherosclerosis may in part relate to a reduction in
extra-arterial inﬂammation.
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